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OBJECTIVE—Adenoviral delivery of hepatocyte growth factor
(HGF) to rodent islets improves islet graft survival and function,
markedly reducing the number of islets required to achieve
glucose control. Here, we asked whether these prior observa-
tions in rodent models extend to nonhuman primate (NHP) islets.
RESEARCH DESIGN AND METHODS—NHP islets were
transduced with murine (Ad.mHGF) or human (Ad.hHGF) ad-
enoviral HGF (Ad.HGF) at low multiplicity of infection and
studied in vitro. To study the function of Ad.HGF-transduced
NHP islets in vivo, a renal subcapsular marginal mass islet
transplant model was developed in streptozotocin-induced dia-
betic NOD-SCID mice.
RESULTS—Baseline glucose values were 454.7  11.3 mg/dl
(n  7). Transplant of 500 NHP islet equivalents (IE) had only a
marginal effect on blood glucose (369.1  9.7 mg/dl, n  5). In
striking contrast, 500 NHP IE transduced with Ad.mHGF
promptly and continuously corrected blood glucose (142.0  6.2
mg/dl, n  7) for the 6-week duration of the experiment.
Unilateral nephrectomy resulted in an immediate return of
glucose to baseline diabetic levels. Interestingly, adenoviral
DNA, as well as mouse HGF (mHGF) mRNA derived from the
adenovirus, were present for 42 days posttransplantation. Sur-
prisingly, transplant of 500 IE with Ad.hHGF, as compared with
Ad.mHGF, resulted in only marginal correction of blood glucose,
suggesting that human HGF is less efﬁcient than mHGF in this
system.
CONCLUSIONS—These studies demonstrate that mHGF mark-
edly improves islet transplant outcomes in the highest preclinical
species examined to date. HGF has promise as an agent that can
improve islet mass and function in transplant models and likely
in other models of types 1 and 2 diabetes. Diabetes 57:
2745–2754, 2008
H
epatocyte growth factor (HGF) is a mesen-
chyme-derived protein originally identiﬁed as a
circulating factor involved in liver regeneration
(1–7). It is now recognized as a widely ex-
pressed mitogen, morphogen, and motogen with actions
on many organs, including the liver, kidney, brain, and
islets (1–7). Mature HGF is a heterodimeric protein com-
posed of a 69-kDa -chain and a 34-kDa -chain. This
mature HGF is generated by cleavage by extracellular
proteases of the inactive pro-HGF precursor to the active
HGF heterodimer.
Hayek and colleagues (1,2) have shown that HGF is a
potent mitogen for fetal and adult human -cells in vitro.
We and others have shown that HGF is a -cell mitogen in
vivo and is also a -cell survival factor (3–7). Transgenic or
viral overexpression of HGF in murine or rat -cells
results in an increased quantity of engrafted -cells and
-cell proliferation. Moreover, HGF upregulates GLUT-2,
glucokinase, and insulin gene expression in -cells in vivo
(4). As a result of these events, HGF-overexpressing islets
sense glucose and secrete insulin in a fashion superior to
normal islets (3,4), and -cell–targeted HGF transgenic
mice develop mild hypoglycemia (3,4). Moreover, using
two different preclinical models, the SCID mouse and the
“Edmonton rat,” we have shown that adenoviral delivery
of HGF to the mouse and rat islets markedly enhances
transplant performance and reduces the number of islets
required for successful islet transplantation (5,6). Finally,
HGF decreases streptozotocin (STZ)-induced -cell death
in RIP-HGF mice (4), and adenoviral-mediated HGF trans-
fer into normal mouse islets improves graft survival (5).
In light of the promise of HGF as a therapeutic agent, we
have now examined the efﬁcacy and safety of HGF in a
higher-level preclinical model, using nonhuman primate
(NHP) islets transplanted into NOD-SCID mice. The re-
sults clearly indicate that NHP islets overexpressing
mouse HGF (mHGF) function more effectively than nor-
mal islets. These anticipated outcomes were accompanied
by three unexpected observations: 1) HGF overexpression
and enhanced -cell engraftment were not associated with
increases in -cell proliferation, 2) abundant adenovirus
expression persisted the full 6 weeks of the experiment,
and 3) murine HGF was superior to human HGF (hHGF) in
this system. These results extend the efﬁcacy of HGF from
rodent islets to the primate level and clearly demonstrate
that HGF should be explored as a therapeutic agent in
human diabetes.
RESEARCH DESIGN AND METHODS
Generation of recombinant adenovirus. Adenoviruses encoding green
ﬂuorescent protein (GFP), -galactosidase (LacZ), and mHGF and hHGF were
prepared as described previously (5,6,8,9). Multiplicity of infection (MOI) was
determined using optical density (OD260) and plaque assay. MOI calculations
assumed 1,000 cells per islet equivalent (IE; 1 IE  125-m-diameter islet).
NHP islets were maintained in culture for 24–48 h before they were
transduced for 1 h with 250–500 MOI of the adenovirus, as previously
described in detail (5,6,8,9) and in Fig. 2. Uninfected and infected islets were
used 24–48 h after infection, as indicated in the Figures. To determine the
efﬁciency of adenoviral transduction, relative semiquantitative PCR analysis
and immunoblots were performed using standard methods as described
previously (5,6,8,9).
NHP islet isolation. NHP islets from cynomolgus donors (Macaca fascicu-
laris, aged 3–10 years) were isolated at the University of Miami using
modiﬁcations (10) of the automated method for human islet isolation (11). All
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of the University of Miami. Isolated islets were shipped in CMRL media
overnight to the University of Pittsburgh.
Insulin content and glucose-stimulated insulin secretion were measured as
described previously (3–6,9). Results are expressed as a percentage of insulin
concentration per IE obtained with uninfected islets at 5 mmol/l glucose.
Islet transplantation. Transduced and nontransduced NHP islets were
transplanted under the kidney capsule of STZ-induced diabetic NOD-SCID
mice as described previously (4,5). Brieﬂy, NOD-SCID mice were rendered
diabetic by injecting twice within 48 h with 150 mg/kg body wt i.p. STZ.
Diabetes was conﬁrmed by the presence of hyperglycemia (300 mg/dl),
polyuria, and weight loss. Random nonfasted blood glucose was measured
from the snipped tail using a Precision Q.I.D. portable glucometer. After 3
consecutive days of hyperglycemia, diabetic NOD-SCID mice were trans-
planted under the left kidney capsule with 500, 1,000, or 2,000 IE 24 h after
transduction as described in the ﬁgures. Blood glucose levels were measured
at days 3, 5, and 7 and then weekly until unilateral nephrectomy at day 42. All
studies were performed with the approval of, and in accordance with,
guidelines established by the University of Pittsburgh institutional animal care
and use committee.
Insulin immunohistochemistry. For insulin immunohistochemistry, kid-
neys were ﬁxed at day 42 after transplantation in Bouin’s solution, parafﬁn
embedded, sectioned, and stained with anti-insulin antibody (Zymed, San
Francisco, CA) at 1:75 dilution. Visualization was achieved using the avidin-
biotin immunoperoxidase complex system (3–6,9). Sections were counter-
stained using hematoxylin.
Quantiﬁcation of transplanted NHP -cell proliferation and cell death.
To assess NHP -cell proliferation in vivo, animals were injected with
bromodeoxyuridine (BrdU) (3–6,9,12,13), and graft-containing kidneys were
harvested on the 5th day after transplantation at 6 h after BrdU injection, ﬁxed
in 4% paraformaldehyde overnight at 4°C, parafﬁn embedded, and sectioned.
In the graft-containing kidneys, three serial sections separated by 25 m were
deparafﬁnized, rehydrated, treated in prewarmed 1 mmol/l HCl for1ha t37°C,
blocked in 2% BSA/PBS for 1 h, and then incubated overnight with anti-BrdU
(Abcam, Cambridge, MA) and anti-insulin antibodies (Zymed). After serial
washing in PBS containing Tween, slides were incubated for 1 h with
secondary antibodies, gel mounted, and coverslipped. Two sections per graft
were analyzed. Three ﬁelds per section were quantiﬁed for BrdU- and
insulin-positive cells. To assess -cell survival, identical procedures were
followed, and sections from the same parafﬁn blocks were costained for
insulin and terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL). The percent of TUNEL- and insulin-positive nuclei were quantiﬁed
as described previously (14) and as described in the legend to Fig. 7.
Adenovirus persistence in vitro and in vivo. For the in vitro studies,
uninfected and infected islets were harvested 24 and 48 h after infection and
were frozen at 80°C until extraction. For the in vivo studies, the left kidneys
containing the NHP islet graft and the right (nontransplanted) kidneys were
harvested on days 1, 7, 14, 28, and 42 and were frozen at 80°C until
extraction. RNA and DNA extraction were performed using Trizol (Invitrogen,
Carlsbad, CA). RNA samples were treated with DNase to prevent DNA
contamination. PCR for adenoviral mouse HGF was performed with the
oligonucleotides described in Fig. 5. As a control to insure that no contami-
nated DNA was ampliﬁed, PCR was performed on RNA samples treated with
DNase with no previous reverse transcription.
Mitogen-activated protein kinase assays. Total p42 and p44 extracellular
signal–regulated kinase (ERK), and their phosphorylated counterparts, were
examined using extracts of primary cultures of mouse arterial smooth muscle
treated with mouse HGF (R&D Systems, Minneapolis, MN) or hHGF (RDI,
Concord, MA) at doses of 25 g/ml as we have described in detail previously
(15) and as described in the legend to Fig. 8. Murine primary arterial smooth
muscle cultures were prepared and documented to represent arterial smooth
muscle cells as described previously (16).
Statistics. Statistical analysis was performed using Student’s t test. All values
are expressed as the means  SE. P  0.05 was considered signiﬁcant.
RESULTS
Immunohistochemical characterization of NHP islets.
Rodent islets, as used in prior rat and mouse studies, are
predominantly homogeneous collections of -cells con-
taining a minority of -, -, PP, and ductal cells, as well as
endothelial cells and contaminating exocrine cells. To
determine the composition of the NHP islets used in the
current studies, and to conﬁrm the purity of the prepara-
tions we used, we examined the -cell composition of our
NHP islets, comparing the number of total islet cells, as
assessed using DAPI (4	,6-diamidino-2-phenylindole) ﬂuo-
rescence, to those that also stained for insulin. As exem-
pliﬁed in Fig. 1, and as described by Cabrera et al. (17), the
large majority of islet cells (Fig. 1B and D for Hoechst
staining) in the NHP islet preparations were insulin-con-
taining -cells (Fig. 1A and C). To conﬁrm this subjective
impression, 66 islets were counted from ﬁve separate NHP
islet preparations, comprising 10,590 total cells. Of these
10,590 total islet cells, 7,467 (72.3  1.9%) were insulin-
positive cells, a percentage comparable or superior to
typical isolated human islet preparations (Fig. 1E and F)
(9,17–20).
Efﬁciency of transduction with Ad.HGF. We next
sought to transduce the NHP islets with adenoviruses
encoding mHGF, hHGF, and two control adenoviruses,
Ad.GFP and LacZ. As in our prior studies with mouse and
rat islets (5,6,9), infection time was 1 h, followed by 24 h of
culture, in an effort to mimic conditions that might be used
with human islet transplantation. To determine the opti-
mal conditions for the adenoviral transduction of NHP
islets that would permit overexpression without adversely
affecting the insulin release, we examined glucose-stimu-
lated insulin secretion 24 h after infection. As shown in
Fig. 2A, transducing NHP islets for1ha t2 5 0M O Io feach
of the viruses did not adversely affect the insulin secretory
response to glucose. However, exposure of NHP islets to
500 MOI of each of the viruses for 1 h caused mild to
markedly attenuated glucose-stimulated insulin secretion,
suggesting that, at 500 MOI of adenovirus, NHP -cell
function was impaired.
As can be seen in Fig. 2B and C, 250 MOI of Ad.mHGF
and Ad.hHGF followed by 24 h in culture resulted in easily
measurable HGF expression at both the mRNA level as
well as the protein level. Low levels of HGF were apparent
in nontransduced and Ad.lacZ- and Ad.GFP-transduced
islets, but the level of overexpression in the Ad.mHGF- and
Ad.hHGF-transduced islets was far higher, perhaps some
10–30 times higher. In addition, Ad.HGF transduction with
250 MOI had no adverse effects on NHP islet insulin
content: normal, Ad.LacZ-, Ad.mHGF- and Ad.hHGF-trans-
duced islets all contained comparable quantities of insulin,
ranging from 
10 to 12 ng/IE. Therefore, infection of NHP
islets for1ha t2 5 0M O Iw a sselected as optimal for
transducing NHP islets in subsequent experiments.
Adenoviral-mediated mHGF transfer into NHP islets
enhances islet transplantation. Our previous studies
had shown that mHGF overexpression improves islet
transplant outcomes in two mouse models and a rat model
of islet transplantation (4–6). The principal goal of the
current study was to determine whether this applies to
islets of higher species. We ﬁrst needed to deﬁne a fully
therapeutic as well as a marginal mass of NHP islets in
NOD-SCID mice. Sham-transplanted mice remained se-
verely hyperglycemic throughout the study (Fig. 3A). In
contrast, mice transplanted with 500 IE achieved border-
line improvement in blood glucose, and 1,000 IE or 2,000
IE was sufﬁcient to achieve stable euglycemia. Therefore,
we selected 500 IE as the marginal mass. To determine
whether adenoviral infection inﬂuenced NHP islet func-
tion or engraftment, we also studied 500 NHP IE trans-
duced with Ad.LacZ. As shown in Fig. 3B, these behaved
comparably with 500 nontransduced normal NHP islets. In
marked contrast to these controls, 500 IE infected with
Ad.mHGF were able to reduce blood glucose concentra-
tions to the near-normal postprandial range (Fig. 3B).
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hances NHP islet engraftment and function.
The left kidney bearing the NHP graft was removed 42
days after transplantation. As shown in Fig. 3B, blood
glucose levels rapidly returned to the pretransplantation
values, indicating that the NHP islets engrafted under the
kidney capsule were responsible for the euglycemia ob-
served in these mice.
Immunohistochemical analysis of kidneys containing
the grafts obtained at 42 days (Fig. 4) revealed the
presence of abundant insulin-positive cells in each kidney
examined from six of the seven Ad.mHGF mice. In con-
trast, insulin-positive cells were not identiﬁed in any of the
10 kidneys from mice transplanted with Ad.LacZ-trans-
duced or uninfected islets.
Adenoviral mHGF DNA and mRNA persist up to 42
days posttransplantation. The preceding data suggested
that gene delivery of mHGF improves NHP islet transplan-
tation outcome and that this effect is sustained for 42 days.
Therefore, we wanted to determine whether this was
associated with long-term expression of viral mHGF DNA
and mRNA. To address this question, we designed primers
that speciﬁcally recognize adenoviral mHGF DNA but not
murine host mHGF DNA or NHP HGF DNA (Fig. 5A). As
shown in Fig. 5B, adenoviral mHGF DNA was easily
detectable 48 h after infection in vitro. Similarly, adenovi-
A
D C
B
F E
FIG. 1. -Cell composition in NHP islets. A–D: Insulin immunoﬂuorescence (green) and Hoechst (blue) staining in NHP islets. E and F: Insulin
immunoﬂuorescence (green) and Hoechst (blue) staining in human islets. Note that the large majority of NHP islets contain 
70% -cells, which
compares very favorably with isolated human islets (9,17,18,20). (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation
of this ﬁgure.)
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in the kidneys that received the graft (Fig. 5C). The
presence of the NHP islet graft was conﬁrmed using
primers speciﬁc for NHP actin. As expected, contralateral
kidneys that did not receive any NHP islet grafts were
negative for the presence of mHGF and NHP actin DNA.
Importantly, as shown in Fig. 5D and E, similar results
were obtained for the adenoviral mHGF mRNA expres-
sion, indicating not only that the Ad.mHGF virus was
present but that it also was functional for the duration of
the study.
Adenovirus-mediated mHGF transfer into NHP islets
did not induce -cell proliferation. HGF has been
shown to stimulate -cell proliferation when added in vitro
(1,2) and in vivo in the RIP-HGF transgenic mouse (3). We
therefore assumed that mHGF would cause increased
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FIG. 2. Glucose-stimulated insulin secretion and HGF expression in nontransduced and transduced NHP islets. A: NHP islets were exposed to
250–500 MOI for 1 h. At 24 h after transduction, groups of 15 IE of similar size were incubated with 5 or 22 mmol/l glucose for 30 min, and insulin
secreted into the media was measured by radioimmunoassay. Results are the means  SE of 5–13 experiments performed in triplicate. The data
are presented as the percentage above the insulin secreted by uninfected islets (100%). B and C: HGF expression as assessed by RT-PCR (B) and
Western blot (C) analysis of RNA extracts and protein extracts obtained from nontransduced NHP islets and islets transduced with 250 MOI of
Ad.LacZ, Ad.GFP, Ad.mHGF, or Ad.hHGF. At 24 h after transduction, islets were harvested and mRNA and protein were extracted. For the
RT-PCR, primers were speciﬁcally designed to amplify either mHGF or hHGF cDNA, as appropriate. HGF was detected using an antibody
recognizing both mHGF and hHGF. Actin was used as an internal control for loading. Note that both Ad.mHGF and Ad.hHGF were able to
transduce NHP islets equally as assessed by RT-PCR and Western blot.
HGF AND PRIMATE ISLETS
2748 DIABETES, VOL. 57, OCTOBER 2008proliferation as assessed using BrdU incorporation in NHP
islets in vivo, in a transplant setting, as it does in vitro or
when overexpressed under the RIP promoter. Figure 6
shows unexpectedly that Ad.mHGF-transduced NHP
-cells did not proliferate at a higher rate than uninfected
NHP -cells, at least at the 3-, 5-, and 10-day time points
after transplantation.
HGF enhances -cell survival in vivo. To determine the
effects of HGF on -cell survival, TUNEL and insulin
costaining were performed both on isolated islets trans-
duced with Ad.mHGF as well as on islet grafts from
transplanted mice 3 days after transplantation. As can be
seen in Fig. 7A and B, -cell death rates in vitro were lower
in Ad.mHGF-transduced islets than in controls, and this
was also true of islet grafts in vivo (Fig. 7C and D).
Ad.hHGF is less effective than Ad.mHGF in NHP
islets. From immunological and therapeutic points of
view, it seemed preferable a priori to use a human version
of HGF in NHP human islet transplantation. On the other
hand, human and mouse HGF share a 93% homology at the
amino acid level and might be presumed to interact with
the c-Met receptor interchangeably. To determine whether
hHGF might be superior in efﬁcacy to mHGF in enhancing
NHP islet transplant outcomes, we prepared an adenovi-
rus encoding hHGF. As shown in Fig. 2B and C, both
Ad.mHGF and Ad.hHGF transduced NHP islets with com-
parable efﬁciency, as assessed by RT-PCR and Western
blotting. Surprisingly, however, as shown in Fig. 3B, 500
NHP IE transduced with Ad.hHGF failed to reduce blood
glucose nearly as effectively as 500 NHP IE transduced
with Ad.mHGF. These observations indicate that Ad.hHGF
is unexpectedly less effective than Ad.mHGF for improv-
ing NHP islet transplant outcomes in this murine recipient
model.
In a preliminary effort to explore the mechanisms re-
sponsible for the superior performance of mHGF com-
pared with hHGF in this system, we examined the ability
of recombinant mHGF and hHGF proteins to stimulate p42
and p44 ERK phosphorylation in NHP islets and in primary
murine vascular smooth muscle cells. Whereas both pep-
tides failed to elicit signiﬁcantly different p42/44 ERK
phosphorylation in NHP Islets (not shown), mHGF was
substantially more effective in stimulating ERK phosphor-
ylation in murine arterial smooth muscle cells (Fig. 8).
These observations suggest that, at least in part, some of
the beneﬁcial effects of HGF may be mediated via host
murine arterial or endothelial cells or their precursors,
rather than on transplanted islet cells, and that mHGF may
be more effective than hHGF in this regard.
DISCUSSION
Whereas transgenic and viral overexpression of HGF in
rodent -cells markedly improves -cell proliferation, sur-
vival, and function in three different in vivo rodent models
(3–6), a necessary intermediate step toward bringing HGF
to human clinical use is demonstrating efﬁcacy in a species
higher in the phylogenetic tree than rodents. Here, we
demonstrate for the ﬁrst time that HGF improves the
quantity of engrafted -cells as well as their function in the
highest preclinical species, the NHP. These studies are
signiﬁcant, for they demonstrate that the efﬁcacy of HGF
clearly merits further study as a therapeutic agent for
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FIG. 4. Islet graft histology 42 days after transplantation. Representa-
tive photomicrographs of kidney sections containing the grafts at day
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org/10.2337/db08-1085 for a high-quality representation of this ﬁgure.)
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negative. INS1 cells transduced with Ad.mHGF were used as positive controls. E: Control PCR from mRNA samples used in D with no reverse
transcriptase (RT). To conﬁrm that no genomic DNA contaminated the samples used in D, PCR was performed on the same samples used in D but
with no reverse transcriptase. INS1 cells transduced with Ad.mHGF were used as a positive control. RT was performed before the PCR. Note that
only the INS1 cells were positive, conﬁrming that samples used in D were free of contaminating DNA.
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diabetes.
In some senses, the results observed might have been
anticipated, based on the efﬁcacy of HGF in rat and mouse
islets. On the other hand, there were three major unantic-
ipated surprises in the current studies. First, HGF has been
shown to drive replication in mouse, rat, as well as fetal,
neonatal, and adult human -cells (1–3). Given the strik-
ingly higher quantity of engrafted -cells in the HGF-
treated grafts (Fig. 4), we had anticipated that -cell
replication would have been increased. On the other hand,
HGF has well-documented salutary effects on -cell sur-
vival as well as -cell function, increasing glucokinase,
GLUT-2, and insulin gene expression (4–6), and each of
these might have contributed to the increase in the quan-
tity of engrafted -cells and/or -cell function. Indeed,
HGF delivery also resulted in a signiﬁcant decrease in NHP
-cell death, both in vitro as well as in vivo (Fig. 7). It is
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FIG. 6. -Cell proliferation and insulin content in islet grafts 5 days after transplant. A: Representative photomicrographs of renal subcapsular
grafts obtained at days 3, 5, and 10 after transplant in control islet grafts or islet grafts transduced with Ad.mHGF showing BrdU (red) and insulin
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increased quantity of engrafted -cells but that this oc-
curred earlier or later than the 3- to 10-day time points
examined here. Although these are critically important
mechanistic questions, we believe that they are better
addressed using human islets in NOD-SCID mice, for two
reasons: 1) additional studies on NHP islets would require
the unnecessary death of additional NHP donors; and 2)i n
the end, answering these questions using human islets is
more relevant to human type 1 and type 2 diabetes than
additional studies using NHP islets.
The second surprise was that hHGF seems to function
less effectively than mHGF in this system, which at ﬁrst
glance more closely approximates a human rather than a
murine -cell transplant model. In theory, this unexpected
species preference might have been attributable to differ-
ences in efﬁciency of transduction or expression of the
two peptides. This seems an unlikely explanation because
both RNA and protein analyses (Fig. 2B and C) suggested
that expression of the two peptides was comparable, and,
since each peptide is a secreted product, that it would
diffuse through an intact islet regardless of the actual
percentage of cells transduced. It is also possible that
mHGF is a superior agonist compared with hHGF for the
NHP HGF receptor, c-Met. Most interestingly, and in our
view perhaps most likely a third explanation, it is also
possible, as also suggested in Fig. 8, that the target of the
HGF in these experiments is not limited to the NHP -cell
c-Met receptor, but also includes murine c-Met receptors
on vascular cells, renal cortical cells, etc., in the murine
recipient. In support of this possibility, both Dong and
colleagues (19) as well as Powers and colleagues (20) have
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FIG. 8. Differential effects mouse HGF and human HGF on p42/44
mitogen-activated protein kinase activity in primary murine arterial
smooth muscle cells. A: Effects of human HGF (hHGF) and mouse HGF
(mHGF) peptides at 25 ng/ml on total ERK and phospho-ERK in
primary cultures of murine aortic smooth muscle cells. Note that
human HGF fails to activate mitogen-activated protein kinase in mouse
arterial smooth muscle cells, whereas mouse HGF readily activates
mitogen-activated protein kinase. To insure that the human HGF was
active, it was also assayed in rat INS-1 cells: the panel on the far right
demonstrates that the identical human HGF preparation that failed to
activate mitogen-activated protein kinase in the vascular smooth
muscle cells (VSMC) was robustly active in INS-1 cells. B: Densitomet-
ric quantiﬁcation of three experiments as outlined in A. These studies
demonstrate that whereas the human HGF peptide is active, it is
unable to activate mitogen-activated protein kinase in murine arterial
smooth muscle cells, in contrast to mouse HGF, which is active in these
same cells. NTx, no treatment.
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ulation of angiogenesis and vascular invasion by host
vasculature into the grafted islets. In this scenario, graft-
derived mHGF could more efﬁciently drive vascular inva-
sion from the host murine kidney than hHGF, which might
be a poor agonist for the murine c-Met receptor in murine
kidney and vasculature. Indeed, as shown in Fig. 8, mHGF
is superior to hHGF as an agonist for at least one signaling
pathway in murine primary arterial smooth muscle cells.
Clearly, the relative effects of mHGF and hHGF on vascu-
larization of islet grafts in this diabetic NOD-SCID mouse
model deserves additional study. The most relevant an-
swers would come from future studies using either a
human-mouse system or a human-human system.
The third surprise is the prolonged duration and appar-
ently high degree of adenovirus expression. We used
adenovirus here as a “poor man’s” protein expression
system to inexpensively produce and locally deliver hHGF
and mHGF to transplanted -cells in vitro and in vivo.
Now-classic studies in humans with cystic ﬁbrosis and
familial hypercholesterolemia have suggested that adeno-
virus is a poor vector for human gene therapy because of
its poor duration of expression and its eliciting of a host
immune response (21,22). On the other hand, most studies
using adenovirus have used immunocompetent hosts.
Here, as in patients with type 1 diabetes who receive islet
transplants (18), the hosts lacked a competent immune
system. This allowed assessment as to how long adenovi-
rus would persist and remain functional in the absence of
immune surveillance. To our surprise, there was little
difference in the presence of adenovirus or the expression
of adenovirally delivered HGF mRNA between the day
after transduction and up to 6 weeks thereafter.
This has both positive and negative implications. On the
positive side, it means that adenovirus may be a very
reasonable gene therapy vector for pancreatic islets in a
transplant setting, where immunosuppression is the norm.
In this setting, adenovirus might provide weeks or months
of effective gene delivery without the risk of permanent
alteration of the host genome, and without the risk of
integration into tumor suppressor genes, as has occurred
with humans receiving lentiviral gene therapy for severe
combined immunodeﬁciency syndrome (23).
On the negative side, to the extent that oncogenic
peptides might be delivered using adenovirus in an immu-
nodeﬁcient setting, one might now need to worry about
prolonged expression and the risk of tumor development.
In the case of HGF and the -cell, this seems like a small
concern, for lifelong (2 years) expression of HGF in
RIP-HGF mice is not associated with tumor development
(3,4). Again, to address these questions, studies currently
ongoing in human islets are exploring the ultimate dura-
tion of expression of adenovirus in humans islets in a
comparable human islet–NOD-SCID mouse model.
The studies described here used an islet transplant
model. However, whereas the results may apply concep-
tually most easily to islet transplantation, the model is
really a laboratory for -cell proliferation, regeneration,
and recovery of -cell function that applies to all forms of
diabetes. It extends far beyond the speciﬁc or narrow goal
of improving islet transplant outcomes, to type 1 and type
2 diabetes.
The complete absence of -cells in control islet grafts
contrasts with the apparent abundance of -cells in the
Ad.mHGF grafts (Fig. 4). This was a consistent ﬁnding: no
grafts were identiﬁed in any of the 10 control kidneys
examined, but they were easily identiﬁed in 6 of 7 Ad.m-
HGF kidneys examined. We have observed this “all or
none” phenomenon previously in transplant experiments
with RIP-HGF or Ad.mHGF-treated transplants into STZ-
induced diabetic mice and rats (3–6). Coupled with the
glycemic data (Fig. 3B), we interpret this to mean that
mHGF enhances engraftment, and if one looked at early
time points (perhaps 7–14 days), grafts would be present
in experimental and control groups, but larger in the HGF
groups. When one waits until day 42, as was the case in
this study, it is reasonable to hypothesize that chronic
hyperglycemia has taken its glucotoxic toll on the control
islets and either abolishes them or makes these grafts so
small as to be nonidentiﬁable. These are questions that can
be addressed by sampling at multiple time points after
transplantation, and we are addressing them in current
studies in human islets transplanted/transduced with
Ad.HGF.
Recombinant production of therapeutic quantities of
complex, posttranslationally processed heterodimeric
peptides such as the HGF family is so expensive as to be
impractical, particularly when, as unexpectedly illustrated
here, the optimal peptide—hHGF versus mHGF—is un-
known. Thus, the production of adenoviral constructs
encoding several HGF family members is relatively inex-
pensive, and, as also shown here, permits direct and
sustained delivery of the HGF peptide to the -cells.
Whether HGF peptides will ultimately best be deployed by
gene delivery or by parenteral injection remains an unset-
tled question. It may be, for the reasons outlined above,
that adenovirus will prove to be the optimal means of HGF
delivery in the setting of diabetes and immunosuppres-
sion. It is equally possible that injection of HGF peptides,
as has been used in rodent models (7), is preferable. Again,
these are questions that are most relevantly addressed in
studies using human islets, which are underway.
Finally, as has been illustrated so nicely with the
epidermal growth factor–gastrin combination (24), it is
in theory possible to use HGF peptides in combination
with other peptides or small molecules that may en-
hance -cell mass and function. For example, combining
a peptide that stimulates -cell replication with one that
stimulates -cell neogenesis may yield synergistic or
complimentary effects.
In summary, these studies demonstrate the efﬁcacy of
HGF peptides in enhancing the quantity of engrafted
-cells and their function in the highest preclinical species,
and they provide strong support for pursuing comparable
studies using human islets cells to address the questions
summarized above.
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